Skip to content
AnalystLens

Halozyme Therapeutics Annual Report, Year Ended Dec 31, 2011

Filing Date
Filed March 12, 2012
Period End
December 31, 2011
Security
HALO
In the record · 2016–202610-K1110-Q338-K141

HALO filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 141 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Mar ’18Mar ’18
  2. FY2019 annual report10-K · Feb ’20Feb ’20
  3. Deal closed8-K · May ’22May ’22
  4. Leadership change8-K · Dec ’25Dec ’25

Summary

Summary of the 10-K filed March 12, 2012. Cited figures are marked; the original filing is the authoritative source.

Halozyme Therapeutics, Inc. is a biopharmaceutical company focused on human enzymes that alter the extracellular matrix.

Its lead enzyme, rHuPH20, underpins its Enhanze drug delivery technology, its Hylenex recombinant product, and its proprietary pipeline, including an ultrafast insulin program (Analog-PH20), PEGPH20 for solid tumors, and HTI-501 for cellulite. The company reported total revenues of $56.1 milliona for 2011, up from $13.6 million in 2010, driven primarily by $18.0 million in upfront license fees from the ViroPharma and Intrexon partnerships and $18.1 million of deferred revenue recognized upon the termination of the Hylenex Partnership with Baxter. Net loss narrowed to $19.8 million, or $0.19 per share, from $53.2 million, or $0.56 per share, in 2010.

Accumulated deficit stood at approximately $245.0 millionb at December 31, 2011. Cash and cash equivalents were $52.8 million at year-end 2011, and the company expects net cash burn of approximately $50.0 to $55.0 million for 2012. Subsequent to year-end, on February 15, 2012, Halozyme sold approximately 7.8 million shares at $10.61 per share, generating approximately $81.8 million in net proceeds before expenses, and management states current cash is sufficient for at least the next twelve months.

Hylenex recombinant was reintroduced to the U.S. market in December 2011 after a May 2010 voluntary recall, and the company now sells it through a distributor while Baxter fills and finishes product under a contract that initially runs through December 2012. The company relies heavily on partner milestones and royalties, with Roche (19%c), Baxter (42%), ViroPharma (22%) and Intrexon (16%) accounting for total 2011 revenues as stated in the filing. The filing also highlights dependence on a small number of contract API manufacturers, the absence of any product currently in a proprietary regulatory approval process, and a history of net losses with no profitability to date.

Key Highlights

  1. Total revenues rose to $56.1 million in 2011 from $13.6 million in 2010, with revenues under collaborative agreements of $54.3 million.
  2. Net loss narrowed to $19.8 million ($0.19 per share) in 2011 from $53.2 million ($0.56 per share) in 2010.
  3. Accumulated deficit of approximately $245.0 million as of December 31, 2011, with the company stating it has never been profitable.
  4. Cash and cash equivalents of $52.8 million at December 31, 2011; a February 2012 public offering raised approximately $81.8 million in net proceeds.
  5. Management expects 2012 net cash burn of approximately $50.0 to $55.0 million and believes current cash is sufficient for at least the next twelve months.
  6. Hylenex recombinant was reintroduced to the U.S. market in December 2011 after the May 2010 recall; the Baxter Hylenex Partnership was terminated effective January 2011.
  7. Lead proprietary programs include Analog-PH20 ultrafast insulin (Phase 2 results announced October 2011), PEGPH20 in Phase 1 and Phase 2 solid tumor trials, and HTI-501 in a Phase 1/2 cellulite trial.

Follow one dollar

For each $1.00 of revenue in FY2011, Halozyme Therapeutics lost $0.35.

  1. Revenue$56.1M100.0%
  2. Cost of revenue−$257,8340.5%
  3. Gross profit$55.8M99.5%
  4. Operating costs−$75.7M134.9%
  5. Operating income−$19.8M35.4%
  6. Interest, other & tax$69,0900.1%
  7. Net income−$19.8M35.2%
Computed from 10-KFY2011filed March 12, 2012Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Financial Statements

FY2011 against FY2010

Line itemFY2011FY2010Change
Revenue$56.09M$13.62M+311.7%
Cost of Revenue$258K$985K−73.8%
Gross Profit$55.83M$12.64M+341.7%
R&D Expenses$57.56M$51.77M+11.2%
SG&A Expenses$18.10M$15.12M+19.7%
Operating Expenses$75.93M$67.88M+11.8%
Operating Income-$19.84M-$54.26M+63.4%
Interest Expense$0——
Net Income-$19.77M-$53.24M+62.9%
EPS (Basic)$-0.19$-0.56+66.1%
Shares Outstanding (Basic)102.57M——

Frequently Asked Questions

  1. What drove the increase in revenue in 2011?

    Total revenues increased to $56.1 million from $13.6 million. The main drivers were $18.0 million in upfront license fees from the ViroPharma and Intrexon partnerships, $11.0 million in milestone payments from Roche, Baxter and ViroPharma, and $18.1 million of previously deferred revenue recognized upon the termination of the Hylenex Partnership with Baxter.

  2. How much cash does Halozyme have and is it enough?

    The company had $52.8 million in cash and cash equivalents at December 31, 2011. Following the February 15, 2012 offering, which generated about $81.8 million in proceeds, management believes current cash will be sufficient to fund operations for at least the next twelve months, though it does not expect revenues to fund operations for several years.

  3. Which partners account for the company's revenues?

    For 2011, the filing states that Roche accounted for 19% of total revenues, Baxter for 42%, ViroPharma for 22% and Intrexon for 16%.

  4. What are the main risks to the company's business?

    Key risks disclosed include the lack of any proprietary product candidate currently in the regulatory approval process, dependence on a small number of contract API manufacturers (Avid and Cook), reliance on partners for development and commercialization of partnered products, a history of net losses with no profitability to date, and the possibility of needing additional capital that may dilute stockholders.